CH IDMP (R5)
1.0.0-ballot - trial-use Switzerland flag

CH IDMP (R5) - Local Development build (v1.0.0-ballot) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 FHIR Standard HL7
... 3 Project Description
... 4 ISO IDMP Standard (ISO 11615)
... 5 IDMP and FHIR
... 6 Swiss IDMP Implementation
... 7 EMA IDMP Implementation and SPOR Overview
... 8 Swissmedic IDMP Implementation
... 9 Comprehensive
... 10 Padcev20
... 11 Padcev30
... 12 Xospata
... 13 Profiles
... 14 Extensions
... 15 Terminology
... 16 Changelog
... 17 Artifacts Summary
.... 17.1 AdministrableProductDefinition
.... 17.2 Bundle
.... 17.3 ClinicalUseDefinition Indication
.... 17.4 DocumentReference
.... 17.5 Ingredient
.... 17.6 ManufacturedItemDefinition
.... 17.7 MedicinalProductDefinition
.... 17.8 Organization
.... 17.9 PackagedProductDefinition
.... 17.10 RegulatedAuthorization
.... 17.11 EMA LOC Identifier
.... 17.12 GLN Identifier
.... 17.13 SMC Identifier
.... 17.14 CH SMC - Authorized Dose Form
.... 17.15 CH - Authorisation Type
.... 17.16 CH - Medicinal Product Name Type
.... 17.17 CH - Other Characteristics Type
.... 17.18 CH Refdata - Marketing Status
.... 17.19 CH SMC - Additional Monitoring Indicator
.... 17.20 CH SMC - Attached Document Type
.... 17.21 CH SMC - Authorisation Category
.... 17.22 CH SMC - Authorisation Status
.... 17.23 CH SMC - Authorised Pharmaceutical Dose Form
.... 17.24 CH SMC - Ingredient Role
.... 17.25 CH SMC - Legal Status of Supply
.... 17.26 CH SMC - Marketing Status
.... 17.27 CH SMC - MedicinalProductCategory
.... 17.28 CH SMC - Pediatric Use Indicator
.... 17.29 CH SMC - Special Precautions for Storage
.... 17.30 CH SMC - Substance
.... 17.31 EDQM - Combination Packaging
.... 17.32 EDQM - Combined Pharmaceutical Dose Form
.... 17.33 EDQM - Combined Term
.... 17.34 EDQM - Packaging
.... 17.35 EDQM - Pharmaceutical Dose Form
.... 17.36 EDQM - Route Of Administration
.... 17.37 EDQM - Unit of Presentation
.... 17.38 EMA - Domain
.... 17.39 EMA - Intended Effect
.... 17.40 EMA - Shelf Life Type
.... 17.41 CH - Authorisation Type
.... 17.42 CH - Medicinal Product Name Type
.... 17.43 CH - Other Characteristics Type
.... 17.44 CH Refdata - Marketing Status
.... 17.45 CH SMC - Additional Monitoring Indicator
.... 17.46 CH SMC - Attached Document Type
.... 17.47 CH SMC - Authorisation Category
.... 17.48 CH SMC - Authorisation Status
.... 17.49 CH SMC - Ingredient Role
.... 17.50 CH SMC - Legal Status of Supply
.... 17.51 CH SMC - Marketing Status
.... 17.52 CH SMC - MedicinalProductCategory
.... 17.53 CH SMC - Pediatric Use Indicator
.... 17.54 CH SMC - Special Precautions for Storage
.... 17.55 CH SMC - Substance
.... 17.56 EDQM - Standard Terms
.... 17.57 EMA - Domain
.... 17.58 EMA - Intended Effect
.... 17.59 EMA - Shelf Life Type
.... 17.60 Application / Assessment Tracking Number
.... 17.61 Clinical Product Identifier
.... 17.62 FOPH Dossier Number
.... 17.63 GLN Identifier
.... 17.64 Global Trade Item Number
.... 17.65 LOC Identifier
.... 17.66 Marketing Authorisation Number
.... 17.67 Medical Product Identifier
.... 17.68 Pharmaceutical Product Identifier
.... 17.69 Swissmedic Location Identifier
.... 17.70 123456002
.... 17.71 12345601
.... 17.72 67211001
.... 17.73 6721101
.... 17.74 68291001
.... 17.75 68291002
.... 17.76 6829103
.... 17.77 6829104
.... 17.78 CH-56891003
.... 17.79 CH-56891003
.... 17.80 CH-68291001
.... 17.81 CH-68291002
.... 17.82 Comprehensive Sample Combipack 20 mg Vaginal Salbe und 100 mg Vaginaltabletten
.... 17.83 Comprehensive Sample Product, Creme and Pessary (Bundle)
.... 17.84 Indication 10004055
.... 17.85 Indication 10046950
.... 17.86 Indication 10046961
.... 17.87 Indication 10050348
.... 17.88 Indication 10057352
.... 17.89 Indication 10059034
.... 17.90 Indication 10060558
.... 17.91 Indication 10081513
.... 17.92 Indication 10081514
.... 17.93 Indication 10084619
.... 17.94 Indication IND-10079528
.... 17.95 MI Clindamycin-100-Pessary
.... 17.96 MI Clindamycin-20-Cream
.... 17.97 MI Enfortumabum-vedotinum-20-Powder
.... 17.98 MI Enfortumabum-vedotinum-30-Powder
.... 17.99 MI Gilteritinibi-hemifumaras-40-Tablet
.... 17.100 Padcev 20 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
.... 17.101 Padcev 20 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung (Bundle)
.... 17.102 Padcev 20 mg, Pulver Information for healthcare professionals
.... 17.103 Padcev 30 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
.... 17.104 Padcev 30 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung (Bundle)
.... 17.105 Patient Information Comprehensive-Sample-Combipack
.... 17.106 Patient Information Xospata, Filmtabletten
.... 17.107 PhP Clindamycin-100-Pessary
.... 17.108 PhP Clindamycin-20-Vaginal Cream
.... 17.109 PhP Enfortumabum-vedotinum-20-Solution
.... 17.110 PHP Enfortumabum-vedotinum-30-Solution
.... 17.111 PhP Gilteritinibi-hemifumaras-40-Filmtabletten
.... 17.112 Professional Information Comprehensive-Sample-Combipack
.... 17.113 Professional Information Xospata, Filmtabletten
.... 17.114 Xospata 40 mg, Filmtabletten
.... 17.115 Xospata 40 mg, Filmtabletten (Bundle)